Administrative Core

ROBIN Oligometastasis（ROBIN OligoMET）中心专注于了解放射治疗如何 影响低容量前列腺癌（PCa）的转移过程。管理核心（Admin Core） 领导人将是Dr. Tran，医学博士，博士（联系PI）和伊莎贝尔劳伦杰克逊（MPI）。陈博士是副主席 他是马里兰州大学（UM）放射肿瘤学研究和教授。他是一个练习辐射 肿瘤学家，因其使用立体定向放射治疗的创新临床试验而获得国际认可。 寡转移性前列腺癌杰克逊博士是非临床放射生物学实验室（NRBL）的主任， 放射肿瘤学系转化放射科学部（DTRS）主任 在UM。她在管理数百万美元的联邦合同研究项目方面有着丰富的经验， 组织损伤和辐射对策。项目领导层由经验丰富、能力强的 研究团队：分子表征试验MCT由Drs. Dr. Dr. Dr. Tran和Mark Mishra领导;项目1 （基因组学、放射组学和液体活检）将由Drs.Tran、Amit Sawant和Lei Ren领导;项目2 （代谢组学和差异）将由Nicole Simone博士领导，他是研究副主席和 托马斯杰斐逊大学（TJU）的放射肿瘤学;将领导资源和交叉培训核心 由Weill-Cornell Medicine（WCM）的Luigi Marchionni博士，UM的Amit Sawant和Lei Ren博士撰写。支持 Drs. Tran和杰克逊在行政核心将是一个项目经理（戴安娜纽曼）。纽曼女士 支持类似项目的丰富经验，包括组织现场访问、外展沟通， 组织研讨会，并与NIH、巴尔达和DARPA协调。我们行政核心的使命 确保研究项目和研究核心能够有效地协同工作， 项目间协作，验证跨分析平台的机制，并交流研究结果 内部和外部。我们寻求成为NCI罗宾计划的动态贡献者，与 NCI和癌症研究界，并与患者倡导者合作，将基础研究联系起来 改善病人的治疗效果ROBIN OligoMET中心的领导层坚定地致力于指导 辐射和转移研究的下一代领导者。我们的ROBIN OligoMET中心包括两个 职业生涯中期的新兴领导者，如分子表征试验负责人（Mishra博士）和核心总监（Dr. Marchionni）。我们的ROBIN OligoMET中心获得了UM放射肿瘤科的资助， 从UMSOM到目标早期教师和来自科学（UIS）背景的教师。我们 管理核心将通过三个目标实现这些目标。目标1：科学和财务管理 ROBIN OligoMET中心。目标2：沟通和审查：外部咨询委员会（EAC），内部 咨询委员会（IAC）、患者倡导者和NCI。目标3：侧重于环境可持续发展的试点研究赠款， 多样性

The ROBIN Oligometastasis (ROBIN OligoMET) Center is focused on understanding how radiation therapy can affect the metastatic process in low-volume prostate cancer (PCa). The Administrative Core (Admin Core) leadership will be Phuoc Tran, M.D., Ph.D. (Contact PI) and Isabel Lauren Jackson (MPI). Dr. Tran is Vice Chair for Research and Professor of Radiation Oncology at the University of Maryland (UM). He is a practicing radiation oncologist with international recognition for his innovative clinical trials using stereotactic radiation in oligometastatic PCa. Dr. Jackson is the Director of the Nonclinical Radiation Biology Laboratory (NRBL) and Director of the Division of Translational Radiation Sciences (DTRS) within the Department of Radiation Oncology at UM. She has deep experience in managing multimillion-dollar federal contract-research programs on normal tissue injury and radiation countermeasures. Project leadership comprises a highly experienced and strong investigative team: Molecular Characterization Trial MCT is led by Drs. Phuoc Tran and Mark Mishra; Project 1 (Genomics, radiomics and liquid biopsies) will be led by Drs. Phuoc Tran, Amit Sawant and Lei Ren; Project 2 (Metabolomics and disparities) will be led by Dr. Nicole Simone Vice Chair for Research and Professor of Radiation Oncology at the Thomas Jefferson University (TJU); Resource and Cross-Training Cores will be led by Drs. Luigi Marchionni from Weill-Cornell Medicine (WCM), Amit Sawant and Lei Ren from UM. Supporting Drs. Tran and Jackson in the Administrative Core will be a Project Manager (Diana Newman). Ms. Newman has significant experience supporting similar programs including organizing site visits, outreach communications, organizing symposia, and coordination with NIH, BARDA and DARPA. The mission of our Administrative Core is to ensure that the research Projects and Research Cores are able to work together efficiently, set priorities for inter-Project collaborations, validate mechanisms across profiling platforms, and communicate research results internally and externally. We seek to be dynamic contributors to the NCI ROBIN Program, to collaborate with the NCI and the cancer research community, and to be a partner with patient advocates to connect basic research to improved patient outcomes. The leadership of ROBIN OligoMET Center is strongly committed to mentoring the next generation of leaders in radiation and metastasis research. Our ROBIN OligoMET Center includes two mid-career emerging leaders as Molecular Characterization Trial Leader (Dr. Mishra) and Core Director (Dr. Marchionni). Our ROBIN OligoMET Center has funding from the UM Radiation Oncology Department and funds from UMSOM to target early stage faculty and faculty from backgrounds underrepresented in science (UIS). Our Admin Core will achieve these goals through three Aims. Aim 1: Scientific and Financial Management of the ROBIN OligoMET Center. Aim 2: Communication and Review: External Advisory Committee (EAC), Internal Advisory Committee (IAC), Patient Advocates, and NCI. Aim 3: Pilot Research Grants Focusing on ESI and Diversity.